India Breast Cancer Treatment Market Assessment, By Type [Ductal Carcinoma In Situ, Invasive Ductal Carcinoma, Lobular Carcinoma In Situ, Invasive Lobular Cancer, Triple Negative Breast Cancer, Inflammatory Breast Cancer, Metastatic Breast Cancer, Breast Cancer During Pregnancy, Others], By Treatment Type [Surgery, Radiation Therapy, Chemotherapy, Hormonal Therapy, Targeted Therapy, Immunotherapy, Others], By End-user [Cancer Research Institutes, Hospitals, Ambulatory Surgical Centers, Others], By Region, Opportunities and Forecast, FY2019-FY2033F

India breast cancer treatment market is projected to witness a CAGR of 11.17% during the forecast period FY2026-FY2033, growing from USD 505.78 million in FY2025 to USD 1179.66 million in FY2033. The market’s growth is augmented by the rising cases of breast cancer in the country, increasing efforts of research organizations to introduce advanced therapeutic solutions to combat breast cancer, and novel launches by leading players of the market. According to the Global Cancer Observatory, IARC-WHO, 2022, 98,337 deaths occurred due to breast cancer among females in 2022 in India.

Report Attribute	Details
Base Year of the Analysis	FY2025
Historical Period	FY2026-FY2033F
Forecast Period	FY2019-FY2024
Projected Growth Rate	CAGR of 11.17% between FY2026 and FY2033
Revenue Forecast in FY2033	USD 1179.66 million

The accessibility of breast cancer treatment is increasing across India due to the rising government initiatives, focus on improving healthcare infrastructure, and growing awareness about the condition. Advancements in medical technology and the introduction of innovative therapies, including targeted therapies, immunotherapies, and antibody-drug conjugates, are broadening the range of effective treatment options available in India. Additionally, the establishment of specialized cancer centers and improved diagnostic facilities are ensuring better disease management and positively influencing the market’s expansion. Meanwhile, late-stage diagnosis in several cases, high costs of treatment, and lack of oncologists in the country pose challenges to the market’s growth.

Increasing Efforts to Improve Breast Cancer Diagnosis Boosts Market Growth

Rising efforts to ensure early detection of breast cancer across the country are propelling the market’s expansion as they are allowing the identification of cases at more treatable stages, augmenting the demand for treatment services. For instance, in November 2024, a team of oncologists under the Cancer Mukt Bharat campaign launched India’s first 24x7 free Pink Cancer Helpline for promoting early detection of breast cancer. The helpline offers guidance via video and phone consultations, including preventive advice and self-examination instructions at no cost. Such initiatives promote awareness about breast cancer, reduce delays, and improve patient access to diagnostic technologies, in turn propelling the expansion of the market.

Increasing Research Efforts of Educational Organizations Support Market Expansion

Rising research efforts by educational organizations are fostering innovation, improving early detection of breast cancer, and enhancing patient outcomes. Institutions like the Cancer Research Institute at the Himalayan Institute of Medical Sciences has launched specialized clinics, including India’s first Young Breast Cancer Clinic, to address the unique requirements of younger patients. Such efforts provide tailored care, promote targeted research, and set new benchmarks for breast cancer treatment and awareness.

Additionally, increasing research efforts are allowing institutes to receive approvals and patents, further encouraging different organizations to continue on with their research efforts. For instance, in February 2025, researchers from IIT Madras successfully developed and patented a next generation drug delivery system for treating breast cancer. The patented technology encapsulates anti-cancer drugs in the nanoparticles that directly target cancer cells, reducing side effects and minimizing damage to healthy tissues.

Development of New Breast Cancer Therapies is Driving the Market’s Growth

The growing efforts of pharmaceutical companies and research organizations to boost the introduction of innovative breast cancer therapies in India is positively influencing the market’s expansion. The availability of novel treatment solutions allows medical professionals to address the critical unmet requirements of the patient population and ensures that patients who previously had limited treatment options available have access to advanced therapies.

Research institutions across India are focusing on developing advanced therapies to improve drug delivery systems in order to combat the rising cases of breast cancer in the country. For instance, in January 2025, researchers from Institute Kolkata and IIT Guwahati developed an innovative injectable hydrogel for targeted breast cancer therapy. The hydrogel releases anti-cancer drugs in a controlled manner. The hydrogel reduces damage to healthy cells and minimizes systemic side effects by ensuring the delivery of chemotherapy drugs directly in the tumor sites.

Hospitals Holds Major Market Share

Hospital account for a significant share of the market as they have access to advanced therapeutic solutions and diagnostic technologies, provide multidisciplinary care, and a comprehensive infrastructure. Additionally, hospitals are better equipped to participate in clinical trials and invest in new technologies, enhancing treatment outcomes. Hospitals also act as key locations for screening programs and cancer awareness, improving the rate of diagnosis and thus treatment uptake. Moreover, a rising number of cancer hospitals are being constructed across the country to ensure that the patient population is provided with the required treatment solutions, thus bolstering the market’s demand. For instance, in December 2024, the newly built Dr Sampat Kumar S. Shivangi Cancer Hospital was inaugurated in Karnataka. Such efforts are increasing the availability of advanced cancer care and improving diagnosis rates and treatment outcomes in underserved regions.

Impact of the U.S. Tariff on India Breast Cancer Treatment Market

Pharmaceutical exports have been exempted from the recent tariffs, however, the medical device industry, which is integral for early detection and treatment of cancer, is expected to face substantial challenges. Healthcare professionals might face challenges in procuring advanced equipment, hindering the diagnostic process, which is particularly crucial for ensuring effective treatment of breast cancer.

Additionally, the tariffs are going to impact Indian medical device manufacturers that export their products to the United States and result in decreased revenues, potentially limiting their resources for research and development activities, constraining the availability of novel diagnostic and therapeutic solutions.

Download Free Sample Report

Report Scope

“India Breast Cancer Treatment Market Assessment, Opportunities and Forecast, FY2019-FY2033F”, is a comprehensive report by Markets and Data, providing in-depth analysis and qualitative and quantitative assessment of the current state of India breast cancer treatment market, industry dynamics, and challenges. The report includes market size, segmental shares, growth trends, opportunities, and forecast between FY2026 and FY2033. Additionally, the report profiles the leading players in the industry, mentioning their respective market share, business models, competitive intelligence, etc.

Report Attribute	Details
Segments Covered	Type, Treatment Type, End-user
Regions Covered	North, East, West and Central, South
Key Companies Profile	Novartis Healthcare Private Limited, Pfizer India Inc., Eisai Pharmaceuticals India Pvt. Ltd., Merck & Co., Inc., Kyowa Kirin Co., Ltd., Eli Lilly and Company (India) Pvt. Ltd., Bristol Myers Squibb India Pvt Ltd, AstraZeneca Pharma India Limited, Sanofi India Limited, Daiichi Sankyo Company, Limited
Customization Scope	15% free report customization with purchase
Pricing and Purchase Options	Avail the customized purchase options to fulfill your precise research needs
Delivery Format	PDF and Excel through email (subject to the license purchased)

In the report, India breast cancer treatment market has been segmented into the following categories: 

• By Type
  • Ductal Carcinoma In Situ (DCIS)
  • Invasive Ductal Carcinoma (IDC)
  • Lobular Carcinoma In Situ (LCIS)
  • Invasive Lobular Cancer (ILC)
  • Triple Negative Breast Cancer
  • Inflammatory Breast Cancer (IBC)
  • Metastatic Breast Cancer
  • Breast Cancer During Pregnancy
  • Other Types
• By Treatment Type
  • Surgery
  • Radiation Therapy
  • Chemotherapy
  • Hormonal Therapy
    • Selective Estrogen Receptor Modulators
    • Aromatase Inhibitors
    • Estrogen Receptor Downregulators
  • Targeted Therapy
    • Abemaciclib
    • Adotrastuzumab Emtansine
    • Everolimus
    • Trastuzumab
    • Ribociclib
    • Palbocicib
    • Pertuzumab
    • Olaparib
    • Others
  • Immunotherapy
  • Others
• By End-user
  • Cancer Research Institutes
  • Hospitals
  • Ambulatory Surgical Centers
  • Others
• By Region
  • North
  • East
  • West and Central
  • South

Key Players Landscape and Outlook

The key players of the market are focusing on launching new drugs to aid the patient population in combating the disease and expanding their presence in the market. For instance, in January 2024, AstraZeneca Pharma India Limited launched Trastuzumab deruxtecan in India for treating adults with metastatic or unresectable HER2 positive breast cancer who have already received an anti-HER2 regimen. The introduction of this drug is seen as a major advancement, providing a transformative option for patients with aggressive breast cancer. Such launches address the critical unmet requirements of the patients by expanding the available treatment options.

Key Players Operating in India Breast Cancer Treatment Market are:

• Novartis Healthcare Private Limited
• Pfizer India Inc.
• Eisai Pharmaceuticals India Pvt. Ltd.
• Merck & Co., Inc.
• Kyowa Kirin Co., Ltd.
• Eli Lilly and Company (India) Pvt. Ltd.
• Bristol Myers Squibb India Pvt Ltd
• AstraZeneca Pharma India Limited
• Sanofi India Limited
• Daiichi Sankyo Company, Limited

If you can't find what you're searching for or have any custom requirements for India breast cancer treatment market, you may approach our team at info@marketsandata.com